We are proud to present to you the new EQA schemes for 2025, allowing more flexibility, time and cost efficiency, ease of purchase, and more.
Our goal is to ensure the highest genomic diagnostic quality from lab to patient, and our updated schemes will help you get there, tailoring our services to your needs.
Some of the updated schemes include:
- For Inherited Retinal Disorders (IRD) we now offer cases involving genes known to cause either syndromic or non-syndromic IRD and an optional case for RPGR ORF15 testing. There will be a minimum of 2 cases for NGS panel testing.
- We have two NEW pilot EQA schemes available for molecular pathology:
- Homologous recombination deficiency (HRD), supported by MSD sponsorship. Places are limited so register early to avoid disappointment.
- Pan-Fusion EQA, for laboratories testing for clinically relevant gene fusions in solid tumours.
- We now offer multiple submission options on our NGS Germline CNV scheme.
- Two distributions in March and September for the cfDNA extraction EQA which is in partnership with SensID and will be fully sponsored by AstraZeneca in 2025. The scheme includes three artificial plasma samples for cell free DNA (cfDNA), designed to mimic nucleosomal circulating tumour DNA (ctDNA) from patients.
- POCT verification package with patient-like swab-based materials to help support laboratories implement and verify POCT devices for MT-RNR1 testing.
View the 2025 catalogue here to see how we can help you improve your diagnostic pipeline.
